Elmind Capital LP Raises Stock Holdings in United Therapeutics Corporation $UTHR

Elmind Capital LP grew its position in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 36.4% in the first quarter, Holdings Channel reports. The fund owned 15,000 shares of the biotechnology company’s stock after buying an additional 4,000 shares during the quarter. United Therapeutics makes up about 2.5% of Elmind Capital LP’s portfolio, making the stock its 14th biggest position. Elmind Capital LP’s holdings in United Therapeutics were worth $8,895,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Arjuna Capital raised its stake in United Therapeutics by 2.8% during the first quarter. Arjuna Capital now owns 662 shares of the biotechnology company’s stock valued at $393,000 after purchasing an additional 18 shares in the last quarter. Sage Rhino Capital LLC increased its holdings in shares of United Therapeutics by 5.1% in the 1st quarter. Sage Rhino Capital LLC now owns 474 shares of the biotechnology company’s stock worth $281,000 after buying an additional 23 shares during the last quarter. Bryn Mawr Trust Advisors LLC increased its holdings in shares of United Therapeutics by 5.4% in the 1st quarter. Bryn Mawr Trust Advisors LLC now owns 465 shares of the biotechnology company’s stock worth $276,000 after buying an additional 24 shares during the last quarter. Meeder Advisory Services Inc. raised its position in shares of United Therapeutics by 4.1% during the 1st quarter. Meeder Advisory Services Inc. now owns 661 shares of the biotechnology company’s stock valued at $392,000 after buying an additional 26 shares in the last quarter. Finally, Independent Advisor Alliance raised its position in shares of United Therapeutics by 3.3% during the 4th quarter. Independent Advisor Alliance now owns 833 shares of the biotechnology company’s stock valued at $406,000 after buying an additional 27 shares in the last quarter. 94.08% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms recently commented on UTHR. TD Cowen reiterated a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. JPMorgan Chase & Co. upped their price objective on United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a research report on Thursday, July 23rd. Raymond James Financial initiated coverage on United Therapeutics in a research note on Friday, April 10th. They issued an “outperform” rating and a $700.00 price objective for the company. Morgan Stanley set a $516.00 target price on United Therapeutics in a report on Thursday, May 7th. Finally, HC Wainwright boosted their target price on United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a research report on Tuesday, March 31st. Eleven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $648.33.

Insider Buying and Selling

In related news, CFO James Edgemond sold 10,000 shares of United Therapeutics stock in a transaction dated Thursday, May 7th. The shares were sold at an average price of $578.58, for a total transaction of $5,785,800.00. Following the completion of the sale, the chief financial officer owned 18,876 shares in the company, valued at $10,921,276.08. This trade represents a 34.63% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Over the last quarter, insiders have sold 493,833 shares of company stock valued at $275,841,047. Company insiders own 8.60% of the company’s stock.

United Therapeutics Price Performance

United Therapeutics stock opened at $527.94 on Tuesday. The firm has a market capitalization of $22.41 billion, a P/E ratio of 19.49, a price-to-earnings-growth ratio of 1.77 and a beta of 0.58. United Therapeutics Corporation has a 1-year low of $272.12 and a 1-year high of $609.35. The company’s 50-day moving average is $547.10 and its 200 day moving average is $531.86.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing the consensus estimate of $7.00 by ($1.18). The business had revenue of $781.50 million for the quarter, compared to analysts’ expectations of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The firm’s quarterly revenue was down 1.6% on a year-over-year basis. During the same quarter last year, the firm earned $6.63 EPS. Research analysts anticipate that United Therapeutics Corporation will post 26.65 earnings per share for the current fiscal year.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.